Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.

Hematology (Amsterdam, Netherlands) - 1 Apr 2018

Qiu Qiao-Cheng, Wang Chao, Bao Xie-Bing, Yang Jing, Shen Hong-Jie, Ding Zi-Xuan, Liu Hong, He Jun, Yao Hong, Chen Su-Ning, Li Zheng, Xue Sheng-Li, Liu Song-Bai

Abstract excerpt

OBJECTIVE: Two distinct forms of FMS-like tyrosine kinase 3 (FLT3) mutations, internal tandem duplication (ITD) in the juxtamembrane domain and point mutation within the activation loop of the tyrosine kinase domain (TKD), have been identified in considerable number of patients with AML. This study was aimed to analyze the impacts of these mutations on clinical outcomes, and assess the efficacy of different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid

Share to Niacinamide

Share to Phenylurea Compounds

Share to Sorafenib

Share to Tandem Repeat Sequences

Share to Transplantation, Homologous

Source

Identifiers

PMID: 28876197
DOI: 10.1080/10245332.2017.1372248

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.PMID 28876197Read ↗

Prognosis and outcome of patients with acute myeloid leukemia based on FLT3‑ITD mutation with or without additional abnormal cytogeneticsSemantic proximity Read ↗

[Clinical Characteristics and Prognosis of Acute Myeloid Leukemia with FLT3-ITD Mutation].Semantic proximity Read ↗

CLINICAL FEATURES OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA CASES AND THE ROLE OF FLT3 INHIBITORS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA: A SINGLE CENTER EXPERIENCESemantic proximity Read ↗

Characteristics and Outcome of FLT3-ITD-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

[Influence of FLT3-ITD Mutation and ITD Length on the Outcome on Patients with Acute Myeloid Leukemia].Semantic proximity Read ↗

[FLT3 mutations in children with acute myeloid leukemia: a single center study].Semantic proximity Read ↗

Inhibition of FLT3 in AML: a focus on sorafenib.Semantic proximity Read ↗

[Research Progress of FLT3 Mutation in Acute Myeloid Leukemia --Review].Semantic proximity Read ↗

Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy.Semantic proximity Read ↗

Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.Semantic proximity Read ↗

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.